Table 1. A list of kinase inhibitors used in this study, their current clinical status and their primary intended targets.

Agent (trade name)	Clinical status	Intended primary targets
Bosutinib (Bosulif)	FDA approved	Src, Bcr-Abl
Dasatinib (Sprycel)	FDA approved	Src, Bcr-Abl,
Dovitinib	Experimental/Clinical trials	Flt3, KIT, FGFR, VEGFR, PDGFR
Erlotinib (Tarvceva)	FDA approved	EGFR
Gefitinib (Iressa)	FDA approved	EGFR
Imatinib (Gleevec)	FDA approved	Bcr-Abl, KIT,
Lapatinib (Tykerb)	FDA approved	EGFR/Her2
Sunitinib (Sutent)	FDA approved	PDGFR, VEGFR, KIT, RET, CSF-1R, Flt3
BEZ235	Experimental/Clinical trials	PI3-K, mTOR